Johnson & Johnson upgraded by Wells Fargo with a new price target
$JNJ
Biotechnology: Pharmaceutical Preparations
Health Care
Wells Fargo upgraded Johnson & Johnson from Equal Weight to Overweight and set a new price target of $212.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/13/2026 | $265.00 | Market Perform → Outperform | Leerink Partners |
| 4/8/2026 | $250.00 | Buy | TD Cowen |
| 1/28/2026 | $262.00 | Equal-Weight → Overweight | Morgan Stanley |
| 11/13/2025 | $230.00 | Sector Outperform | Scotiabank |
| 10/20/2025 | $203.00 | Neutral → Outperform | Daiwa Securities |
| 10/3/2025 | $212.00 | Equal Weight → Overweight | Wells Fargo |
| 9/23/2025 | $206.00 | Neutral → Buy | Guggenheim |
| 7/23/2025 | Hold → Buy | Erste Group |
Leerink Partners upgraded Johnson & Johnson from Market Perform to Outperform and set a new price target of $265.00
TD Cowen resumed coverage of Johnson & Johnson with a rating of Buy and set a new price target of $250.00
Morgan Stanley upgraded Johnson & Johnson from Equal-Weight to Overweight and set a new price target of $262.00
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
Investment includes new advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility to scale the Company's U.S. Vision operations, enhance supply chain resilience, and meet the needs of more than 40 million patients Investment is part of the Company's ongoing $55 billion commitment to U.S. manufacturing, research and development, and technology through early 2029 Building on more than 40 years of leadership in Florida, the investment supports 3,500 Jacksonville employees and strengthens Johnson & Johnson's $6 billion annual economic impact across the state Johnson & Johnson (NYSE:JNJ) (the "Company"), healthcare's leading, most comprehensive
TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the third positive study in recent months from Johnson & Johnson's bispecific portfolio and is the first Phase 3 study of a GPRC5D bispecific investigational combinationResults reinforce Johnson & Johnson's leadership in multiple myeloma, advancing bispecific combinations earlier in the treatment journey, and expanding options to match the right treatment to the right patient and stage of diseaseSTOCKHOLM, June 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announc
Expanded U.S. availability paired with new patient lifestyle quiz encourages informed decision-making ahead of cataract surgery. Cataracts are one of the leading causes of vision impairment.1 Nearly 20% of Americans aged 40+ live with cataracts that make everyday tasks more challenging, yet only 5% have had cataract surgery.2 Over half a million eyes worldwide have already experienced clearer, extended range of vision with TECNIS PureSee IOL after cataract surgery.3,4 97% of patients would recommend TECNIS PureSee IOL to friends or family.5 Johnson & Johnson (NYSE:JNJ) is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC-IOLs)
For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin
For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not
For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione
SD - JOHNSON & JOHNSON (0000200406) (Filer)
13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)
8-K - JOHNSON & JOHNSON (0000200406) (Filer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
Johnson & Johnson (NYSE:JNJ) (the "Company") today announced the appointment of Ryan Koors to Vice President, Investor Relations, effective May 7, 2026. Mr. Koors will report to Johnson & Johnson's Executive Vice President and Chief Financial Officer, Joseph J. Wolk. He succeeds Darren Snellgrove who is leaving the company to become the chief financial officer of Halozyme. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430443361/en/Ryan Koors, Vice President, Investor Relations, Johnson & Johnson, effective May 7, 2026. "Ryan's appointment underscores the deep bench of financial talent within Johnson & Johnson and our commitm
Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o
Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv
Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 15th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Ryan Koors, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the w
Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a 3.1% increase in the quarterly dividend, from $1.30 per share to $1.34 per share, marking the 64th year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.36 per share compared to the previous rate of $5.20 per share. The next quarterly dividend is payable on June 9, 2026 to shareholders of record at the close of business on May 26, 2026. The ex-dividend date is May 26, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, tr
2026 First-Quarter reported sales growth of 9.9% to $24.1 Billion with operational growth of 6.4%* and adjusted operational growth of 5.3%* 2026 First-Quarter earnings per share (EPS) of $2.14 and adjusted EPS of $2.70 Company increases 2026 guidance with estimated reported sales of $100.8 Billion or 7.0% at the midpoint, and adjusted EPS4 of $11.55 or 7.1% at the midpoint Solidifying path to double-digit growth by the end of the decade, with significant progress for patients with the approvals of ICOTYDE the first-and-only targeted oral peptide for plaque psoriasis, TECVAYLI plus DARZALEX FASPRO as early as second line for patients with relapsed/refractory multiple myeloma, VARIP
SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)
SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)
SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)